The Latin America generic injectables market was valued at USD 2.27 Billion in 2025, driven by the favorable regulatory policies and the rising healthcare needs in the region. The market is expected to grow at a CAGR of 8.00% during the forecast period of 2026-2035, with the values likely to rise from USD 4.90 Billion by 2035.
Base Year
Historical Period
Forecast Period
In March 2023, GlaxoSmithKline (GSK) signed deals with three companies that will allow them to manufacture generic versions of HIV preventive injectable drug cabotegravir. The rise in such initiatives to address drug shortages is expected to influence the Latin America generic injectables market share.
The surge in the demand for cost-effective medications to address the rising healthcare needs is driving the market growth.
Recent market trends include the patent expiration of brand-name injectables and increased government and regulatory support that stimulate market entry of generic injectables.
Compound Annual Growth Rate
8%
Value in USD Billion
2026-2035
*this image is indicative*
Generic injectables are similar to branded injectable medications in terms of active ingredients, strength, and clinical performance. However, they are typically sold at a lower cost and thus experience increased government and regulatory support for their manufacture and market penetration. The growing burden of chronic diseases and the increasing aging population are contributing to the expansion of the global generic injectables market. Further, the surge in the demand for cost-effective medications to address the rising healthcare needs is driving the Latin America generic injectables market growth.
In March 2023, GlaxoSmithKline (GSK) signed deals with three companies (Aurobindo Pharma, Cipla, and Viatris) that will allow them to manufacture cost-effective generic versions of its long-acting HIV preventive medicine (injectable drug cabotegravir) with a supply in 90 countries, primarily in lower-income countries with a high prevalence of HIV. GSK also announced a program with the Medicines Patent Pool (a United Nations-backed healthcare organization) in July 2022, with the aim to offer accelerated access to new HIV therapies in poor countries. Through this program, the company claims to introduce the generic form of its injection by 2026. The rise in such initiatives to combat drug shortages and address the need for affordable life-saving medications is poised to fuel the Latin America generic injectables market demand.
The patent expiration of brand-name injectables stimulates the entry of generic versions which directly impacts the market dynamics signfficantly. For instance, the patent of Danish firm Novo Nordisk’s popular diabetes and weight-loss subcutaneous injectable drug, semaglutide, will expire in 2026 in Brazil. In May 2023, the Brazilian federal court denied semaglutide patent extension request by the company, which means that the injectable formulations of semaglutide, Wegovy and Ozempic, will experience competition from first generics just after two years from now. Thus, the expiration of market exclusivity of original injectables is projected to elevate the market value in the forecast period.
The report offers a detailed analysis of the market based on the following segments:
Product Type
Market Breakup by Container Type
Market Breakup by Application
Market Breakup by Route of Administration
Market Breakup by Distribution Channel
Market Breakup by Region
The key features of the market report include patent analysis, grants analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
Pfizer has a flourishing business in the sterile injectables category, offering both generic and branded products. It acquired Hospira, the world’s leading provider of injectable drugs and infusion technologies, in September 2015 , to reinforce its position in the generic injectables market.
This American global pharmaceutical and healthcare corporation is one of the largest generic drug manufacturers in the world, specializing in developing complex injectables across a broad range of therapeutic areas.
Biocon is a fully integrated biopharmaceutical company that develops complex generic formulations and active pharmaceutical ingredients (APIs).
Lupin Limited ranks as one of the largest generic pharmaceutical companies by revenue globally. Recently, it received regulatory approval in the United States to market a generic drug to treat bacterial infections.
*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*
Other players in the market include Aurobindo Pharma Limited and Sun Pharmaceutical Industries Ltd.
Upto 15% Off
USD
$2699 $2429
$4299 $3869
$5799 $4949
$6999 $5949
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
The market attained a value of about USD 2.27 Billion in 2025 driven by the rising patent expirations of branded drugs in the region.
The market is anticipated to grow at a CAGR of 8.00% during the forecast period of 2026-2035, likely to reach a market value of USD 4.90 Billion by 2035.
The increasing prevalence of chronic diseases and the growing aging population are fuelling the demand for the market.
One of the significant trends in the market is the rising patent expiration of branded injectables. For instance, the patent of Danish firm Novo Nordisk’s popular diabetes and weight-loss injectable drug, semaglutide, will expire in 2026 in Brazil.
Based on the product type, the market is segmented into large molecule injectables and small molecule injectables. Large molecule injectables are further divided into monoclonal antibodies (mAbs), insulin, others.
Container types available in the market include vials, premix, prefilled syringes, and ampoules, among others.
Major applications of the market include oncology, cardiovascular, CNS, infectious diseases, and autoimmune disorders, among others.
The market breakup by route of administration includes intravenous, intramuscular, and subcutaneous, among others.
Distribution channels of the market are hospitals and retail pharmacies, among others.
The market segmentation by countries includes Brazil, Argentina, and Mexico, among others.
The key players in the market are Pfizer Inc., Viatris Inc., Biocon, Lupin, Aurobindo Pharma Limited, and Sun Pharmaceutical Industries Ltd.
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| REPORT FEATURES | DETAILS |
| Base Year | 2025 |
| Historical Period | 2019-2025 |
| Forecast Period | 2026-2035 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Product Type |
|
| Breakup by Container Type |
|
| Breakup by Application |
|
| Breakup by Route of Administration |
|
| Breakup by Distribution Channel |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Datasheet
One User
USD 2,699
USD 2,429
tax inclusive*
Single User License
One User
USD 4,299
USD 3,869
tax inclusive*
Five User License
Five User
USD 5,799
USD 4,949
tax inclusive*
Corporate License
Unlimited Users
USD 6,999
USD 5,949
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share